The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1275
December 3, 2007
View Complete Issue         Table of Contents 2019 
Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria
December 3, 2007 (Issue: 1275)
Levocetirizine (Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H1-antihistamine cetirizine (Zyrtec), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria
Article code: 1275a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.